GGAL vs JHG

The deterministic health profile is critically weak, highlighted by a Piotroski F-Score of 2/9 and a massive valuation gap where the current price ($47.93) trades at a significant premium to the Graham Number ($8.34) and Intrinsic Value ($6.23). While long-term price performance has been exceptional, current fundamentals show severe deterioration, including a negative YoY revenue growth of 10% and a catastrophic earnings surprise trend (-149.13% over the last 4 quarters). The dividend is unsustainable with a payout ratio of 123.58%, suggesting capital erosion. Despite bullish analyst targets, the hard data indicates a high-risk, overvalued asset.

JHG presents a stark contradiction between valuation and operational health, highlighted by a weak Piotroski F-Score of 3/9. While the company exhibits explosive YoY earnings growth (244.6%) and trades significantly below its Graham Number ($62.47) and Intrinsic Value ($154.29), the low F-Score suggests deteriorating fundamental trends. This, combined with a very bearish technical trend (10/100) and low insider sentiment, indicates that the market is pricing in risks not immediately apparent in the growth metrics. The stock is a classic 'deep value' candidate that requires caution due to declining operational quality.